Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records in obstructive sleep apnoea with obesity

13 records bearing on obstructive sleep apnoea with obesity.

Showing 0 records on this page

Records

13 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SURMOUNT-OSA-1TirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2024High
SURMOUNT-OSA-2TirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2024High
SURMOUNT-OSA-1-OLEprogramme recordTirzepatidePhase 3ReportedSingle-arm open-label2024Very low
SURMOUNT-OSA-2-BODY-COMPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2024Very low
SURMOUNT-OSA-1-ELDERLYprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled2024Very low
SCALE-SLEEP-APNOEALiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled3592016Moderate
SCALE-SLEEP-APNOEA-RENAL-IMPprogramme recordLiraglutidePhase 1ReportedPhase 1 ascending dose2016Very low
SCALE-SLEEP-APNOEA-PKprogramme recordLiraglutidePhase 1ReportedPhase 1 ascending dose2016Very low
SCALE-SLEEP-APNOEA-DDIprogramme recordLiraglutidePhase 1ReportedRandomised crossover2016Very low
SCALE-SLEEP-APNOEA-HEPATIC-IMPprogramme recordLiraglutidePhase 1ReportedPhase 1 ascending dose2016Very low
SCALE-SLEEP-APNOEA-REGIONAL-JPprogramme recordLiraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled2016Very low
TRIUMPH-OSARetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledNot rated
TRIUMPH-OSA-OLEprogramme recordRetatrutidePhase 3OngoingSingle-arm open-labelVery low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.